
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is a promising biotechnology company with a unique product offering that has the potential to drive significant growth in the future. The company's collaboration with ALC and their positive recent earnings report indicate strong potential for increased utilization and market share in the premium category. Additionally, the company's solid financials and promising pipeline for light adjustable lenses make it a strong investment option.
Bears say
RxSight is facing various risks that may impede the company's growth potential, including lackluster adoption due to the additional capital equipment required, challenges in commercial execution, intensifying competition in the intraocular lens market, and the possibility of a dilutive financing round. The company's recently announced collaboration with Alcon may showcase its technology's value, but overall, disappointing underlying sales in the second quarter and lowered revenue guidance for 2026 suggest a weakening performance. While RxSight did report better-than-expected gross margin and in-line revenue for the quarter, its operating expenses were higher than anticipated, and the company still faces challenges in utilization and margin contraction. Based on these factors, it may be prudent to maintain a negative outlook on RxSight's stock, with potential upside drivers including faster LDD installed base growth, higher utilization, and improved LAL volumes and margins.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares